Fennec Pharmaceuticals (STU:RV41) 3-Year Revenue Growth Rate : 392.20% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals 3-Year Revenue Growth Rate?

Fennec Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2023 was €0.33.

During the past 12 months, Fennec Pharmaceuticals's average Revenue per Share Growth Rate was 1258.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 392.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Fennec Pharmaceuticals was 392.20% per year. The lowest was 392.20% per year. And the median was 392.20% per year.

Competitive Comparison of Fennec Pharmaceuticals's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Fennec Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

Fennec Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Fennec Pharmaceuticals (STU:RV41) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Fennec Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (STU:RV41) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

FENC:USA FRX:Canada

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines